Investigational drug · Phase 3
177Lu-PSMA-617
Also called: Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetan
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
84
Any phase or sponsor naming "177Lu-PSMA-617"
First trial start
2021
Jun 9, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "177Lu-PSMA-617", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostatic Neoplasms
- Prostatic Neoplasm
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "177Lu-PSMA-617" as an intervention, largest first.
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04720157 · 1,144 participants · Start Jun 9, 2021 · Primary completion Jan 13, 2025
Drug: 177Lu-PSMA-617; 68Ga-PSMA-11 and 2 more · For: Prostatic Neoplasms
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 164 sites in all
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06855277 · 940 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 29, 2028
Drug: AAA817; ARPI and 1 more · For: Prostate Cancer
Sites: Homewood, Alabama; Tucson, Arizona; Orange, California · 106 sites in all
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate CancerPivotal-lookingCompleted
EndocyteIndustry
NCT03511664 · 861 participants · Start May 29, 2018 · Primary completion Jan 27, 2021
Drug: 177Lu-PSMA-617 · For: Prostate Cancer
Sites: Scottsdale, Arizona; Tucson, Arizona; Los Angeles, California · 88 sites in all
- Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05803941 · 700 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 20, 2033
Drug: AAA617 · For: Prostate Cancer
Sites: Scottsdale, Arizona; Orange, California; Santa Monica, California · 54 sites in all
- Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)Pivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT06496581 · 500 participants (planned) · Start Sep 12, 2024 · Primary completion Feb 1, 2033
Drug: 177Lu-PMSA-617; Standard of Care · For: Prostate Cancer Metastatic
Sites: Angers, France; Bordeaux, France; Brest, France · 25 sites in all
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04689828 · 469 participants · Start Jun 15, 2021 · Primary completion Oct 2, 2022
Drug: 177Lu-PSMA-617; 68Ga-PSMA-11 and 1 more · For: Prostatic Neoplasms
Sites: Denver, Colorado; Gainesville, Florida; New Orleans, Louisiana · 72 sites in all
- Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06780670 · 443 participants (planned) · Start Feb 27, 2025 · Primary completion Jun 27, 2028
Drug: Investigators choice of SoC; AAA817 and 2 more · For: Prostate Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; Palo Alto, California · 93 sites in all
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerPivotal-lookingNot yet recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT07852195 · 432 participants (planned) · Start Jan 6, 2027 · Primary completion Mar 31, 2029
Drug: Abiraterone Acetate; Cabazitaxel and 8 more · For: Metastatic Castration-Resistant Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
- Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerPivotal-lookingSuspended
Mayo ClinicAcademic, hospital or other
NCT06200103 · 236 participants (planned) · Start May 3, 2024 · Primary completion Dec 31, 2029
Drug: Lutetium Lu 177 Vipivotide Tetraxetan · For: Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- ¹ࠝࠝ Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer With Complex Renal Conditions : A Case Series.
Usmani S, Al Balushi A, Al Saadi S, et al. · Clin Nucl Med 2026
- Quantitative Imaging Evaluation of Structural and Densitometric Changes in Major Salivary Glands After 177Lu PSMA Radioligand Therapy.
Köylüce N, Demir F · Ann Nucl Med 2026
- Single-Time-Point Time-integrated Activity Estimation for Dosimetry in 177Lu-PSMA Therapy: Evaluation of Analytical and Machine Learning Methods.
Mansouri Z, Fitzpatrick K, Fredericks M, et al. · Clin Nucl Med 2026
- Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer.
Juthani R, Zhong C, Tarhini A, et al. · Prostate Cancer Prostatic Dis 2026
- Reverse PSMA Theranostic Discordance: Reproducible ¹ࠝࠝLu-PSMA-617 Uptake in Skeletal Metastases Inconspicuous on Serial ¹ࠞF-PSMA-1007 PET/CT.
Mahdi RA, Sood A, Sharma S, et al. · Clin Nucl Med 2026
- PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan.
Hirata K, Watanabe S, Wakabayashi H, et al. · Int J Urol 2026
Also in development for Prostatic Neoplasms
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- ARDTPhase 32 trials
Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- JNJ-101556143Phase 32 trials
Johnson & Johnson (Janssen) · Prostatic Neoplasms
- GV20-0251Phase 23 trials
GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
- QLH12016Phase 22 trials
Qilu Pharmaceutical Co., Ltd. · Prostatic Neoplasms, Advanced Prostate Cancer
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.